RxDoctor Payments Data

Sarah Gordon

Physician Assistant · Orlando, FLNPI 1528274750

Payments from drug & device makers

$4,484in general payments, 2019–2025

Across 237 payments — averaging $18.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$996
  • AstraZeneca$860
  • AbbVie$603
  • Lilly USA, LLC$509
  • Pfizer$143
  • Biohaven Pharmaceutical Holding Company Ltd.$120
  • plus $1K from 31 others

What the payments were for

  • Food & beverage$4,484100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,484 in reported general payments places this provider in the 85th percentile of 8,062 physician assistant providers in Florida.

See all physician assistant providers in Florida

Medicare billing

Part B allowed, 2024
$181,938
Medicare patients
534
Services billed
3,157

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide41$44,366
EliquisApixaban24$36,717
JardianceEmpagliflozin18$21,721
JanumetSitagliptin Phos/Metformin Hcl18$7,993
Levothyroxine Sodium186$2,039
SynthroidLevothyroxine Sodium36$1,976
Rosuvastatin Calcium143$1,693
Venlafaxine Hcl ErVenlafaxine Hcl23$1,455
Omeprazole87$1,382
Metoprolol Succinate70$1,209
Wixela InhubFluticasone Propion/Salmeterol14$1,122
Pantoprazole Sodium57$1,032
Atorvastatin Calcium159$1,000
Amlodipine Besylate120$983
Gabapentin49$918

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$996$44,36641 claims
PfizerEliquis$143$36,71724 claims
Boehringer IngelheimJardiance$19$21,72118 claims
MerckJanumet$19$7,99318 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$32$2,039186 claims
AbbVieSynthroid$603$1,97636 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,062 physician assistant providers in Florida.

Other physician assistant in Orlando

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →